Federal Register / Vol. 66, No. 104 / Wednesday, May 30, 2001 / Notices 29337

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Evaluate whether

the proposed collectionof information is

necessary for the proper performance of

the National Cancer Institute, including

whether the information will have

practical utility; (2) evaluate the

accuracy of the NCI’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) enhance the enhance the quality

utility, and clarity of the information to

be collected; (4) minimize the burden of

the collection of information on those

who are to respond, including the use

of appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Dr. Terry L.

Thomas, National Cancer Institute, EPS

7100, 6120 Executive Boulevard,

Rockville, MD, 29892–7238, or call the

non-toll-free number (301) 496–6600.

Comments Due Date: Comments

regarding this information collection are

best assured of having their full effect if

received on or before July 30, 2001.

Dated: May 16, 2001.

Reesa Nichols,

NCI Project Clearance Liaison.

[FR Doc. 01–13484 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Improving

DNA, RNA and Protein availability in Fixed

Tissue.

Date: June 15, 2001.

Time: 8 a.m. to 2 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Cancer Institute, 6130

Executive Boulevard, Conference Room F,

Rockville, MD 20852.

Contact Person: Gerald G. Lovinger,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8101, Rockville, MD

20892–7405, 301/496–7987.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: May 23, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13539 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections 55b(c)(4)

and 552(b)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel Research in

State and Community Tobacco Control.

Date: June 17–18, 2001.

Time: 6:30 PM to 5 PM.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn, 8120 Wisconsin

Avenue, Bethesda, MD 20814.

Contact Person: C.M. Kerwin, Scientific

Review Administrator, Special Review and

Resources Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8039, Rockville, MD

20892–7405, 301/496–7421.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: May 23, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13540 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Spores in

Skin Cancer.

Date: June 21–22, 2001.

Time: 8 a.m. to 6 p.m.